Literature DB >> 17957209

Surgery Insight: carotid endarterectomy--which patients to treat and when?

Kumar Rajamani1, Seemant Chaturvedi.   

Abstract

Over the past 15 years, we have witnessed a resurgence of surgery for prevention of ischemic stroke. Landmark trials including the North American Symptomatic Carotid Endarterectomy Trial and the European Carotid Surgery Trial have explored the role of carotid endarterectomy in this context, comparing the procedure with best medical treatment in patients with high-grade stenosis of the internal carotid artery and transient ischemic attack or minor nondisabling stroke in the same territory. Here, we discuss the lessons learnt from these trials, and review the Asymptomatic Carotid Atherosclerosis Study and the Asymptomatic Carotid Surgery Trial, which attempted to resolve the rather vexing issue of surgical treatment for patients with asymptomatic internal carotid artery stenosis. We also review the best medical treatment for patients undergoing carotid endarterectomy in the perioperative period, and examine the risk of ischemic stroke after CABG surgery, both when this procedure is performed alongside endarterectomy and when CABG surgery and endarterectomy are performed as a two-staged procedure.

Entities:  

Mesh:

Year:  2007        PMID: 17957209     DOI: 10.1038/ncpcardio1008

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  2 in total

1.  Combining carotid endarterectomy with off-pump coronary artery bypass graft surgery is safe and effective.

Authors:  Arun Garg; Atma Ram Bansal; Dilip Singh; Manisha Mishra; Pooja Sharma; Ravi Ratan Kasliwal; Naresh Trehan
Journal:  Ann Indian Acad Neurol       Date:  2015 Oct-Dec       Impact factor: 1.383

2.  Experiences with carotid endarterectomy at Sree Chitra Tirunal Institute.

Authors:  Madathipat Unnikrishnan; Shivananda Siddappa; Rajesh Anto; Vivek Babu; Benny Paul; Thirur Raman Kapilamoorthy; Sivasubramanian Sivasankaran; Samavedam Sandhyamani; Rupa Sreedhar; Kuruppath Radhakrishnan
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.